287 related articles for article (PubMed ID: 27923516)
1. Therapy-related myelodysplastic syndromes, or are they?
Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM
Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516
[TBL] [Abstract][Full Text] [Related]
2. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
3. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: toward a risk-adapted treatment approach.
Faltas B; Zeidan A; Gergis U
Expert Rev Hematol; 2013 Oct; 6(5):611-24. PubMed ID: 24094045
[TBL] [Abstract][Full Text] [Related]
6. Current therapy of myelodysplastic syndromes.
Zeidan AM; Linhares Y; Gore SD
Blood Rev; 2013 Sep; 27(5):243-59. PubMed ID: 23954262
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?
Brierley CK; Steensma DP
Curr Opin Hematol; 2016 Mar; 23(2):167-74. PubMed ID: 26717194
[TBL] [Abstract][Full Text] [Related]
10. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
[TBL] [Abstract][Full Text] [Related]
11. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
Mishra A; Anasetti C
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.
Nichols G; de Castro K; Wei LX; Griffin M; Lin N; Oratzi A; Murty VV; Troxel A; Vahdat L; Hesdorffer C
Leukemia; 2002 Sep; 16(9):1673-9. PubMed ID: 12200680
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.
Zeidan AM; Shallis RM; Wang R; Davidoff A; Ma X
Blood Rev; 2019 Mar; 34():1-15. PubMed ID: 30314642
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic Syndromes: Diagnosis and Treatment.
Steensma DP
Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS.
Amigo ML; del Cañizo MC; Rios A; Garcia MA; Caballero MD; Martin A; Bermejo N; Vilches P; San Miguel JF
Bone Marrow Transplant; 1999 May; 23(10):997-1002. PubMed ID: 10373064
[TBL] [Abstract][Full Text] [Related]
16. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
[TBL] [Abstract][Full Text] [Related]
17. Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?
Wermke M; Gloaguen S; Platzbecker U
Curr Hematol Malig Rep; 2015 Sep; 10(3):329-33. PubMed ID: 26126601
[TBL] [Abstract][Full Text] [Related]
18. Prognosis and therapy of secondary myelodysplastic syndromes.
Estey EH
Haematologica; 1998 Jun; 83(6):543-9. PubMed ID: 9676028
[TBL] [Abstract][Full Text] [Related]
19. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
20. Pediatric myelodysplastic syndromes.
Niemeyer CM; Kratz CP; Hasle H
Curr Treat Options Oncol; 2005 May; 6(3):209-14. PubMed ID: 15869732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
